| IL-6 in inflammation, immunity, and disease T Tanaka, M Narazaki, T Kishimoto Cold Spring Harbor perspectives in biology 6 (10), a016295, 2014 | 5217 | 2014 |
| Interleukin-6 family of cytokines and gp130 T Kishimoto, S Akira, M Narazaki, T Taga Blood 86 (4), 1243-1254, 1995 | 1806 | 1995 |
| Structure and function of a new STAT-induced STAT inhibitor T Naka, M Narazaki, M Hirata, T Matsumoto, S Minamoto, A Aono, ... Nature 387 (6636), 924-929, 1997 | 1750 | 1997 |
| Immunotherapeutic implications of IL-6 blockade for cytokine storm T Tanaka, M Narazaki, T Kishimoto Immunotherapy 8 (8), 959-970, 2016 | 821 | 2016 |
| Targeting interleukin-6 signaling in clinic S Kang, T Tanaka, M Narazaki, T Kishimoto Immunity 50 (4), 1007-1023, 2019 | 813 | 2019 |
| Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. M Murakami, M Narazaki, M Hibi, H Yawata, K Yasukawa, M Hamaguchi, ... Proceedings of the National Academy of Sciences 88 (24), 11349-11353, 1991 | 784 | 1991 |
| Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine Y Maeda, T Kurakawa, E Umemoto, D Motooka, Y Ito, K Gotoh, K Hirota, ... Arthritis & rheumatology 68 (11), 2646-2661, 2016 | 669 | 2016 |
| Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130 M Narazaki, K Yasukawa, T Saito, Y Ohsugi, H Fukui, Y Koishihara, ... | 576 | 1993 |
| Cardiotrophin-1 Activates a Distinct Form of Cardiac Muscle Cell Hypertrophy: ASSEMBLY OF SARCOMERIC UNITS IN SERIES VIA gp130/LEUKEMIA INHIBITORY FACTOR RECEPTOR-DEPENDENT … KC Wollert, T Taga, M Saito, M Narazaki, T Kishimoto, CC Glembotski, ... Journal of Biological Chemistry 271 (16), 9535-9545, 1996 | 502 | 1996 |
| Interleukin (IL-6) immunotherapy T Tanaka, M Narazaki, T Kishimoto Cold Spring Harbor perspectives in biology 10 (8), a028456, 2018 | 387 | 2018 |
| Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. M Narazaki, BA Witthuhn, K Yoshida, O Silvennoinen, K Yasukawa, ... Proceedings of the National Academy of Sciences 91 (6), 2285-2289, 1994 | 374 | 1994 |
| Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice T Naka, T Matsumoto, M Narazaki, M Fujimoto, Y Morita, Y Ohsawa, ... Proceedings of the National Academy of Sciences 95 (26), 15577-15582, 1998 | 359 | 1998 |
| Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling M Narazaki, M Fujimoto, T Matsumoto, Y Morita, H Saito, T Kajita, ... Proceedings of the National Academy of Sciences 95 (22), 13130-13134, 1998 | 339 | 1998 |
| Historical overview of the interleukin-6 family cytokine S Kang, M Narazaki, H Metwally, T Kishimoto Journal of Experimental Medicine 217 (5), e20190347, 2020 | 324 | 2020 |
| Therapeutic targeting of the interleukin-6 receptor T Tanaka, M Narazaki, T Kishimoto Annual review of pharmacology and toxicology 52 (1), 199-219, 2012 | 322 | 2012 |
| Differential processing of stromal-derived factor-1α and stromal-derived factor-1β explains functional diversity M De La Luz Sierra, F Yang, M Narazaki, O Salvucci, D Davis, ... Blood 103 (7), 2452-2459, 2004 | 294 | 2004 |
| Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130. T Taga, M Narazaki, K Yasukawa, T Saito, D Miki, M Hamaguchi, S Davis, ... Proceedings of the National Academy of Sciences 89 (22), 10998-11001, 1992 | 254 | 1992 |
| The two-faced cytokine IL-6 in host defense and diseases M Narazaki, T Kishimoto International journal of molecular sciences 19 (11), 3528, 2018 | 248 | 2018 |
| Apoptosis-derived membrane vesicles drive the cGAS–STING pathway and enhance type I IFN production in systemic lupus erythematosus Y Kato, JH Park, H Takamatsu, H Konaka, W Aoki, S Aburaya, M Ueda, ... Annals of the rheumatic diseases 77 (10), 1507-1515, 2018 | 241 | 2018 |
| The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab Y Shima, Y Kuwahara, H Murota, S Kitaba, M Kawai, T Hirano, J Arimitsu, ... Rheumatology 49 (12), 2408-2412, 2010 | 240 | 2010 |
